Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp
AMZN Amazon.com Inc
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Closing Price
$10.71
Day's Change
1.10 (11.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.87
Day's Low
9.70
Volume
(Light)
Volume:
14,076,771

10-day average volume:
22,065,488
14,076,771
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.